Immunocore Q2 FY26 net loss narrows to $0.8 million; revenue rises 18% to $115.9 million

Reuters2026/08/06 11:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immunocore posted Q2 net sales of $115.9 million, up 18% year over year, driven by higher volumes in the US and international regions.
Net loss narrowed to $808,000, or $0.02 per share, from a $10.3 million loss a year earlier.
R&D expense rose to $73.9 million from $69 million, reflecting advancement of clinical programs including three Phase 3 studies.
Cash, cash equivalents and marketable securities totaled $880 million at June 30, 2026, up from $864.2 million at Dec. 31, 2025.
Enrollment in the Phase 3 TEBE-AM trial in previously treated advanced cutaneous melanoma neared the 540-patient target, with topline data possible by end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immunocore Q2 FY26 net loss narrows to $0.8 million; revenue rises 18% to $115.9 million

You may also like

Crypto prices